3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Conditions
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
3
Pancreatic Neoplasms
3
Cholangiocarcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Neoplasm Metastasis
2
Carcinoma, Non-Small-Cell Lung
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urothelial Bladder Carcinoma
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Stomach Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Pharyngeal Neoplasms
1
Oropharyngeal Neoplasms
1
Oligometastatic Prostate Cancer
1
Mouth Neoplasms
1
Melanoma
1
Lung Diseases
1
Locally Advanced Pancreatic Cancer
1
Locally Advanced Cervical Cancer
1
Liver Neoplasms
1
Liposarcoma
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Interventions
Methotrexate
6
Dactinomycin
5
camrelizumab
3
Flow Cytometry
3
Drug Therapy
3
toripalimab
2
pembrolizumab
2
apatinib
2
Vacuum Curettage
2
Psychiatric Rehabilitation
2
Methylprednisolone
2
Leucovorin
2
Immunologic Techniques
2
Cyclophosphamide
2
Alemtuzumab
2
zimberelimab
1
dostarlimab
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
Vincristine
1
Tacrolimus
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Prednisone
1
Paclitaxel
1
Moxifloxacin
1
Microarray Analysis
1
Methods
1
Interleukin-12 Subunit p35
1
Interleukin-11
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Gestational Trophoblastic Disease
×
zimberelimab
×
Clear all
NCT06790706
2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2
Recruiting
154 enrolled